Details of the Drug

General Information of Drug (ID: DMXYJOB)

• Drug Name: Phentolamine
• Synonyms: Dibasin; Fentolamin; Fentolamina; Phenotolamine; Phentalamine; Phentolaminum; Regitin; Regitine; Regitipe; Regityn; Rogitine; Phentolamine mesylate [USAN]; Phentolamine methanesulfonate; C 7337; C 7337 Ciba; Fentolamina [INN-Spanish]; Phentolamine (INN); Phentolamine [INN:BAN]; Phentolamine, methyl sulfonate; Phentolaminum [INN-Latin]; Vasomax (TN); 2-((N-(m-Hydroxyphenyl)-p-toluidino)methyl)-2-imidazoline; 2-(N'-p-Tolyl-N'-m-hydroxyphenylaminomethyl)-2-imidazoline; 2-(N-(m-Hydroxyphenyl)-p-toluidinomethyl)imidazoline; 2-(m-Hydroxy-N-p-tolylanilinomethyl)-2-imidazoline; 3-[(4,5-dihydro-1H-imidazol-2-ylmethyl)(4-methylphenyl)amino]phenol; 3-[N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-4-methylanilino]phenol

Indication

Disease Entry	ICD 11	Status	REF
Dermal necrosis	MC85	Approved	[1], [2]

• Therapeutic Class: Antihypertensive Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 281.35
  Topological Polar Surface Area (xlogp); 2.6
  Rotatable Bond Count (rotbonds); 4
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 3
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 42 mL/min/kg [4]
  Half-life: The concentration or amount of drug in body reduced by one-half in 19 minutes [4]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 15.232 micromolar/kg/day [5]
• Chemical Identifiers:
  Formula: C17H19N3O
  IUPAC Name: 3-[N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-4-methylanilino]phenol
  Canonical SMILES: CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O
  InChI: InChI=1S/C17H19N3O/c1-13-5-7-14(8-6-13)20(12-17-18-9-10-19-17)15-3-2-4-16(21)11-15/h2-8,11,21H,9-10,12H2,1H3,(H,18,19)
  InChIKey: MRBDMNSDAVCSSF-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 5775
  ChEBI ID: CHEBI:8081
  CAS Number: 50-60-2
  DrugBank ID: DB00692
  TTD ID: D01JUF
  VARIDT ID: DR00754

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Antagonist	[6]

Molecular Expression Atlas of This Drug

• The Studied Disease: Dermal necrosis
• ICD Disease Classification: MC85

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine D2 receptor (D2R)	DTT	DRD2	2.50E-02	-0.08	-0.49

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Phentolamine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Phentolamine and Cariprazine.	Bipolar disorder [6A60]	[17]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Phentolamine and Olopatadine.	Conjunctiva disorder [9A60]	[18]
Selegiline	DM6034S	Moderate	Additive hypotensive effects by the combination of Phentolamine and Selegiline.	Depression [6A70-6A7Z]	[19]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Phentolamine and Isocarboxazid.	Depression [6A70-6A7Z]	[19]
Tranylcypromine	DMGB5RE	Moderate	Additive hypotensive effects by the combination of Phentolamine and Tranylcypromine.	Depression [6A70-6A7Z]	[19]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Phentolamine and OPC-34712.	Depression [6A70-6A7Z]	[17]
Phenelzine	DMHIDUE	Moderate	Additive hypotensive effects by the combination of Phentolamine and Phenelzine.	Depression [6A70-6A7Z]	[19]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Phentolamine and Procarbazine.	Hodgkin lymphoma [2B30]	[19]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Phentolamine and ITI-007.	Insomnia [7A00-7A0Z]	[17]
Ozanimod	DMT6AM2	Moderate	Additive hypotensive effects by the combination of Phentolamine and Ozanimod.	Multiple sclerosis [8A40]	[19]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Phentolamine and Promethazine.	Nausea/vomiting [MD90]	[17]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Phentolamine and Safinamide.	Parkinsonism [8A00]	[19]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Phentolamine and Rasagiline.	Parkinsonism [8A00]	[19]
Tamsulosin	DM5QF9V	Moderate	Additive hypotensive effects by the combination of Phentolamine and Tamsulosin.	Prostate hyperplasia [GA90]	[20]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Phentolamine and Silodosin.	Prostate hyperplasia [GA90]	[20]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Phentolamine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[17]
Mesoridazine	DM2ZGAN	Moderate	Additive hypotensive effects by the combination of Phentolamine and Mesoridazine.	Schizophrenia [6A20]	[17]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Phentolamine and Aripiprazole.	Schizophrenia [6A20]	[17]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Phentolamine and Iloperidone.	Schizophrenia [6A20]	[17]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Phentolamine and Paliperidone.	Schizophrenia [6A20]	[17]
Perphenazine	DMA4MRX	Moderate	Additive hypotensive effects by the combination of Phentolamine and Perphenazine.	Schizophrenia [6A20]	[17]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Phentolamine and Molindone.	Schizophrenia [6A20]	[17]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Phentolamine and Thiothixene.	Schizophrenia [6A20]	[17]
Trifluoperazine	DMKBYWI	Moderate	Additive hypotensive effects by the combination of Phentolamine and Trifluoperazine.	Schizophrenia [6A20]	[17]
Risperidone	DMN6DXL	Moderate	Additive hypotensive effects by the combination of Phentolamine and Risperidone.	Schizophrenia [6A20]	[17]
Amisulpride	DMSJVAM	Moderate	Additive hypotensive effects by the combination of Phentolamine and Amisulpride.	Schizophrenia [6A20]	[17]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Phentolamine and Asenapine.	Schizophrenia [6A20]	[17]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Phentolamine and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[17]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Phentolamine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[21]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 502).
• [2] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 040235.
• [3] BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
• [4] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [5] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [6] Nesfatin-1 exerts cardiovascular actions in brain: possible interaction with the central melanocortin system. Am J Physiol Regul Integr Comp Physiol. 2009 Aug;297(2):R330-6.
• [7] The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
• [8] Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
• [9] CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
• [10] Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
• [11] Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
• [13] Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
• [14] [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
• [15] Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
• [16] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [17] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
• [18] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
• [19] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
• [20] Product Information. Flomax (tamsulosin). Boehringer-Ingelheim, Ridgefield, CT.
• [21] Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.